AEON Biopharma Inc(AEON) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
October 8 at 4:45 PM ET (Korea 10/9 05:45)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -3.77 | Insider Own | 52.32% | Shs Outstand | 26.3M | Perf Week | 6.9% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | 33.06% | Insider Trans | 4.61% | Shs Float | 23.8M | Perf Month | 34.2% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -0.08 | Inst Own | 31.71% | Short Float | 12.4% | Perf Quarter | -35.83% |
| Income | -0.05B | P/S | - | EPS this Y | 89.32% | Inst Trans | 50.41% | Short Ratio | 0.35 | Perf Half Y | -62.65% |
| Sales | 0.00B | P/B | - | EPS next 5Y | 67.95% | ROA | -621.7% | Short Interest | 2.95M | Perf YTD | -71.82% |
| Book/sh | -0.58 | P/C | 4.51 | EPS past 3/5Y | 47.46% -253.12% | ROE | - | 52W High | -78.62% ($1.45) | Perf Year | -66.3% |
| Cash/sh | 0.07 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 74.94% ($0.18) | Perf 3Y | -99.94% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 35.03% | Gross Margin | - | Volatility(W/M) | 15.43% 15.86% | Perf 5Y | -99.96% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.04 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.54 | EPS Q/Q | 96.18% | Profit Margin | - | RSI (14) | 58.79 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.54 | Sales Q/Q | - | SMA20 | 12.75% ($0.27) | Beta | 0.68 | Target Price | $1.82 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/12 | SMA50 | 16.48% ($0.27) | Rel Volume | 0.13 | Prev Close | $0.31 |
| Employees | 8 | LT Debt/Eq | - | EPS/Sales Surpr. | 91.11% - | SMA200 | -58.37% ($0.74) | Avg Volume(3M) | 8.45M | Price | $0.31 |
| IPO | 2021/4/12 | Option/Short | No/Yes | Trades | 1234 | Volume | 1,103,602 | Change | -0.4% |
💉 Eon Bio Pharma () is a biotech company headquartered in Irvine, California, USA, that develops its proprietary botulinum toxin **"ABP-450"** specifically for therapeutic purposes. The company is running clinical trials in neurology-related indications such as spastic cervical dystonia, migraine, gastroparesis, and post-traumatic stress disorder (PTSD), with its key differentiator being a focus on purely therapeutic (rather than cosmetic) uses of botulinum toxin.
Over the past 1 year, on the lower side
79% below its 1-year high.
Traded less than usual That is 13% of its average volume.
AEON has weak earnings and a weak balance sheet
Review management risk carefully before investing
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +89.3% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +77% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 31.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #480 of 592 in the industry
Based on market cap of $15M.
FAQ
What kind of company is AEON?
AEON belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of AEON?
The market cap of AEON is approximately $15M, ranking 5,348 within its sector.
What is the 52-week high and low for AEON?
AEON has recorded a 52-week high of $1.45 and a low of $0.18.
